SNES vs. TCON, MBIO, AEMD, NSTGQ, KRBP, EVOK, NAVB, NEXI, CING, and VRPX
Should you be buying SenesTech stock or one of its competitors? The main competitors of SenesTech include TRACON Pharmaceuticals (TCON), Mustang Bio (MBIO), Aethlon Medical (AEMD), NanoString Technologies (NSTGQ), Kiromic BioPharma (KRBP), Evoke Pharma (EVOK), Navidea Biopharmaceuticals (NAVB), NexImmune (NEXI), Cingulate (CING), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "medical" sector.
TRACON Pharmaceuticals (NASDAQ:TCON) and SenesTech (NASDAQ:SNES) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.
TRACON Pharmaceuticals has a net margin of 0.00% compared to TRACON Pharmaceuticals' net margin of -646.27%. SenesTech's return on equity of -10.25% beat TRACON Pharmaceuticals' return on equity.
11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.2% of SenesTech shares are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of SenesTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, SenesTech's average media sentiment score of 0.00 equaled TRACON Pharmaceuticals'average media sentiment score.
SenesTech received 55 more outperform votes than TRACON Pharmaceuticals when rated by MarketBeat users. Likewise, 65.44% of users gave SenesTech an outperform vote while only 58.50% of users gave TRACON Pharmaceuticals an outperform vote.
TRACON Pharmaceuticals currently has a consensus price target of $60.00, suggesting a potential upside of 3,074.60%. SenesTech has a consensus price target of $3.50, suggesting a potential upside of 359.80%. Given SenesTech's higher possible upside, equities research analysts plainly believe TRACON Pharmaceuticals is more favorable than SenesTech.
TRACON Pharmaceuticals has higher revenue and earnings than SenesTech.
TRACON Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, SenesTech has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
Summary
TRACON Pharmaceuticals beats SenesTech on 9 of the 14 factors compared between the two stocks.
Get SenesTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNES and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNES and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SenesTech Competitors List
Related Companies and Tools
